Assays for histone deacetylases

Current Topics in Medicinal Chemistry

Volumn 9, Issue 3, 2009, Pages 227-234

  Hauser, Alexander Thomas ^a   Jung, Mira ^b   Jung, Manfred ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; DNA; FLUOROOROTIC ACID; GREEN FLUORESCENT PROTEIN; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; ROMIDEPSIN; SIRTUIN; TRANSFORMING GROWTH FACTOR BETA; TRICHOSTATIN A; TUMOR SUPPRESSOR PROTEIN; VORINOSTAT;

ACETYLATION; BIOCHEMISTRY; CELL ASSAY; CELL PROLIFERATION; CYTOMEGALOVIRUS; DEVELOPMENTAL BIOLOGY; DNA MODIFICATION; DRUG APPROVAL; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME STRUCTURE; ENZYME SUBSTRATE; EPIGENETICS; FLUORESCENCE ANALYSIS; FLUORESCENCE POLARIZATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE EXPRESSION; GENE SILENCING; GENETIC CODE; HERITABILITY; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; MALIGNANT NEOPLASTIC DISEASE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENESIS; PHENOTYPE; PROMOTER REGION; RADIOACTIVITY; REPORTER GENE; REVIEW; SIMIAN VIRUS 40; WESTERN BLOTTING;

DRUG DISCOVERY; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 65449156432     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609788085269     Document Type: Review

References (66)

1. Wilson, K. J.; Witter, D. J.; Grimm, J. B.; Siliphaivanh, P.; Otte, K. M.; Kral, A. M.; Fleming, J. C.; Harsch, A.; Hamill, J. E.; Cruz, J. C.; Chenard, M.; Szewczak, A. A.; Middleton, R. E.; Hughes, B. L.; Dahlberg, W. K.; Secrist, J. P.; Miller, T. A. Phenylglycine and phenylalanine derivatives as potent and selective HDAC1 inhibitors (SHI-1). Bioorg. Med. Chem. Lett. 2008, 18, 1859-1863.
2. Cheng, D.; Yadav, N.; King, R. W.; Swanson, M. S.; Weinstein, E. J.; Bedford, M. T. Small molecule regulators of protein arginine methyltransferases. J. Biol. Chem. 2004, 279, 23892-23899.
3. Stimson, L.; Rowlands, M. G.; Newbatt, Y. M.; Smith, N. F.; Raynaud, F. I.; Rogers, P.; Bavetsias, V.; Gorsuch, S.; Jarman, M.; Bannister, A.; Kouzarides, T.; McDonald, E.; Workman, P.; Aherne, G. W. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. Mol. Cancer Ther. 2005, 4, 1521-1532.
4. Stockwell, B. R.; Haggarty, S. J.; Schreiber, S. L. High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications. Chem. Biol. 1999, 6, 71-83.
5. Wynne Aherne, G.; Rowlands, M. G.; Stimson, L.; Workman, P. Assays for the identification and evaluation of histone acetyl-transferase inhibitors. Methods 2002, 26, 245-253.
6. Spannhoff, A.; Heinke, R.; Bauer, I.; Trojer, P.; Metzger, E.; Gust, R.; Schule, R.; Brosch, G.; Sippl, W.; Jung, M. Target-based approach to inhibitors of histone arginine methyltransferases. J. Med. Chem. 2007, 50, 2319-2325.
7. Haggarty, S. J.; Koeller, K. M.; Wong, J. C.; Grozinger, C. M.; Schreiber, S. L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. USA 2003, 100, 4389-4394.
8. Forsgren, A.; Sjoquist, J. "Protein A" from S. aureus. I. Pseudoimmune reaction with human gamma-globulin. J. Immunol. 1966, 97, 822-827.
9. Su, G. H.; Sohn, T. A.; Ryu, B.; Kern, S. E. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res. 2000, 60, 3137-3142.
10. Glaser, K. B.; Li, J.; Aakre, M. E.; Morgan, D. W.; Sheppard, G.; Stewart, K. D.; Pollock, J.; Lee, P.; O'Connor, C. Z.; Anderson, S. N.; Mussatto, D. J.; Wegner, C. W.; Moses, H. L. Transforming growth factor beta mimetics: discovery of 7-[4-(4-cyanophenyl) phenoxy]-heptanohydroxamic acid, a biaryl hydroxamate inhibitor of histone deacetylase. Mol. Cancer Ther. 2002, 1, 759-768.
11. Lain, S.; Hollick, J. J.; Campbell, J.; Staples, O. D.; Higgins, M.; Aoubala, M.; McCarthy, A.; Appleyard, V.; Murray, K. E.; Baker, L.; Thompson, A.; Mathers, J.; Holland, S. J.; Stark, M. J.; Pass, G.; Woods, J.; Lane, D. P.; Westwood, N. J. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 2008, 13, 454-463.
12. Remiszewski, S. W. The discovery of NVP-LAQ824: from concept to clinic. Curr. Med. Chem. 2003, 10, 2393-2402.
13. Kim, Y. B.; Lee, K. H.; Sugita, K.; Yoshida, M.; Horinouchi, S. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 1999, 18, 2461-2470.
14. Bedalov, A.; Gatbonton, T.; Irvine, W. P.; Gottschling, D. E.; Simon, J. A. Identification of a small molecule inhibitor of Sir2p. Proc. Natl. Acad. Sci. USA 2001, 98, 15113-15118.
15. Yang, X. J.; Seto, E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat. Rev. Mol. Cell Biol. 2008, 9, 206-218.
16. Smith, J. S.; Avalos, J.; Celic, I.; Muhammad, S.; Wolberger, C.; Boeke, J. D. SIR2 family of NAD(+)-dependent protein deacetylases. Methods Enzymol. 2002, 353, 282-300.
17. Marks, P.; Rifkind, R. A.; Richon, V. M.; Breslow, R.; Miller, T.; Kelly, W. K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 2001, 1, 194-202.
18. Marks, P. A. Discovery and development of SAHA as an anticancer agent. Oncogene 2007, 26, 1351-1356.
19. Kolle, D.; Brosch, G.; Lechner, T.; Lusser, A.; Loidl, P. Biochemical methods for analysis of histone deacetylases. Methods 1998, 15, 323-331.
20. Darkin-Rattray, S. J.; Gurnett, A. M.; Myers, R. W.; Dulski, P. M.; Crumley, T. M.; Allocco, J. J.; Cannova, C.; Meinke, P. T.; Colletti, S. L.; Bednarek, M. A.; Singh, S. B.; Goetz, M. A.; Dombrowski, A. W.; Polishook, J. D.; Schmatz, D. M. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl. Acad. Sci. USA 1996, 93, 13143-13147.
21. Taunton, J.; Hassig, C. A.; Schreiber, S. L. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 1996, 272, 408-411.
22. Nare, B.; Allocco, J. J.; Kuningas, R.; Galuska, S.; Myers, R. W.; Bednarek, M. A.; Schmatz, D. M. Development of a scintillation proximity assay for histone deacetylase using a biotinylated peptide derived from histone-H4. Anal. Biochem. 1999, 267, 390-396.
23. Hoffmann, K.; Brosch, G.; Loidl, P.; Jung, M. A non-isotopic assay for histone deacetylase activity. Nucleic Acids Res. 1999, 27, 2057-2058.
24. Hoffmann, K.; Heltweg, B.; Jung, M. Improvement and validation of the fluorescence-based histone deacetylase assay using an internal standard. Arch. Pharm. 2001, 334, 248-252.
25. Heltweg, B.; Jung, M. A microplate reader-based nonisotopic histone deacetylase activity assay. Anal. Biochem. 2002, 302, 175-183.
26. Heltweg, B.; Jung, M. Eosin Y as an internal standard for a plate reader based quantitation of a histone deacetylase substrate. Arch. Pharm. 2002, 335, 296-300.
27. Heltweg, B.; Jung, M. A homogeneous nonisotopic histone deacetylase activity assay. J. Biomol. Screen. 2003, 8, 89-95.
28. Heltweg, B.; Trapp, J.; Jung, M. In vitro assays for the determination of histone deacetylase activity. Methods 2005, 36, 332-337.
29. Wegener, D.; Wirsching, F.; Riester, D.; Schwienhorst, A. A fluorogenic histone deacetylase assay well suited for high-throughput activity screening. Chem. Biol. 2003, 10, 61-68.
30. Heltweg, B.; Dequiedt, F.; Verdin, E.; Jung, M. Nonisotopic substrate for assaying both human zinc and NAD+-dependent histone deacetylases. Anal. Biochem. 2003, 319, 42-48.
31. Hoffmann, K.; Söll, R. M.; Beck-Sickinger, A. G.; Jung, M. Fluorescence-labeled octapeptides as substrates for histone deacetylase. Bioconjug. Chem. 2001, 12, 51-55.
32. Blackwell, L.; Norris, J.; Suto, C. M.; Janzen, W. P. The use of diversity profiling to characterize chemical modulators of the histone deacetylases. Life Sci. 2008, 82, 1050-1058.
33. Heltweg, B.; Dequiedt, F.; Marshall, B. L.; Brauch, C.; Yoshida, M.; Nishino, N.; Verdin, E.; Jung, M. Subtype selective substrates for histone deacetylases. J. Med. Chem. 2004, 47, 5235-5243.
34. Riester, D.; Wegener, D.; Hildmann, C.; Schwienhorst, A. Members of the histone deacetylase superfamily differ in substrate specificity towards small synthetic substrates. Biochem. Biophys. Res. Commun. 2004, 324, 1116-1123.
35. Sankaranarayanapillai, M.; Tong, W. P.; Maxwell, D. S.; Pal, A.; Pang, J.; Bornmann, W. G.; Gelovani, J. G.; Ronen, S. M. Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy. Mol. Cancer Ther. 2006, 5, 1325-1334.
36. Bonfils, C.; Kalita, A.; Dubay, M.; Siu, L. L.; Carducci, M. A.; Reid, G.; Martell, R. E.; Besterman, J. M.; Li, Z. Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay. Clin. Cancer Res. 2008, 14, 3441-3449.
37. Hildmann, C.; Ninkovic, M.; Dietrich, R.; Wegener, D.; Riester, D.; Zimmermann, T.; Birch, O. M.; Bernegger, C.; Loidl, P.; Schwienhorst, A. A new amidohydrolase from Bordetella or Alcaligenes strain FB188 with similarities to histone deacetylases. J. Bacteriol. 2004, 186, 2328-2339.
38. Baumann, M.; Sturmer, R.; Bornscheuer, U. T. A high-throughput-screening method for the identification of active and enantioselective hydrolases. Angew. Chem., Int. Ed. Engl. 2001, 40, 4201-4204.
39. Fatkins, D. G.; Zheng, W. A spectrophotometric assay for histone deacetylase 8. Anal. Biochem. 2008, 372, 82-88.
40. Riester, D.; Hildmann, C.; Schwienhorst, A.; Meyer-Almes, F. J. Histone deacetylase inhibitor assay based on fluorescence resonance energy transfer. Anal. Biochem. 2007, 362, 136-141.
41. Marcotte, P. A.; Richardson, P. L.; Guo, J.; Barrett, L. W.; Xu, N.; Gunasekera, A.; Glaser, K. B. Fluorescence assay of SIRT protein deacetylases using an acetylated peptide substrate and a secondary trypsin reaction. Anal. Biochem. 2004, 332, 90-99.
42. Vaziri, H.; Dessain, S. K.; Ng Eaton, E.; Imai, S. I.; Frye, R. A.; Pandita, T. K.; Guarente, L.; Weinberg, R. A. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001, 107, 149-159.
43. Borra, M. T.; Smith, B. C.; Denu, J. M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 2005, 280, 17187-17195.
44. Burke, T. J.; Loniello, K. R.; Beebe, J. A.; Ervin, K. M. Development and application of fluorescence polarization assays in drug discovery. Comb. Chem. High Throughput Screen. 2003, 6, 183-194.
45. Jameson, D. M.; Croney, J. C. Fluorescence polarization: past, present and future. Comb. Chem. High Throughput Screen. 2003, 6, 167-173.
46. Milne, J. C.; Lambert, P. D.; Schenk, S.; Carney, D. P.; Smith, J. J.; Gagne, D. J.; Jin, L.; Boss, O.; Perni, R. B.; Vu, C. B.; Bemis, J. E.; Xie, R.; Disch, J. S.; Ng, P. Y.; Nunes, J. J.; Lynch, A. V.; Yang, H.; Galonek, H.; Israelian, K.; Choy, W.; Iffland, A.; Lavu, S.; Medvedik, O.; Sinclair, D. A.; Olefsky, J. M.; Jirousek, M. R.; Elliott, P. J.; Westphal, C. H. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007, 450, 712-716.
47. Mazitschek, R.; Patel, V.; Wirth, D. F.; Clardy, J. Development of a fluorescence polarization based assay for histone deacetylase ligand discovery. Bioorg. Med. Chem. Lett. 2008, 18, 2809-2812.
48. Xu, W. S.; Parmigiani, R. B.; Marks, P. A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26, 5541-5552.
49. Waltregny, D.; De Leval, L.; Glenisson, W.; Ly Tran, S.; North, B. J.; Bellahcene, A.; Weidle, U.; Verdin, E.; Castronovo, V. Expression of histone deacetylase 8, a class I histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues. Am. J. Pathol. 2004, 165, 553-564.
50. Durst, K. L.; Lutterbach, B.; Kummalue, T.; Friedman, A. D.; Hiebert, S. W. The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain. Mol. Cell Biol. 2003, 23, 607-619.
51. Martin, M.; Kettmann, R.; Dequiedt, F. Class IIa histone deacetylases: regulating the regulators. Oncogene 2007, 26, 5450-5467.
52. Zhang, Y.; Li, N.; Caron, C.; Matthias, G.; Hess, D.; Khochbin, S.; Matthias, P. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J. 2003, 22, 1168-1179.
53. Kölle, D.; Brosch, G.; Lechner, T.; Lusser, A.; Loidl, P. Biochemical methods for analysis of histone deacetylases. Methods 1998, 15, 323-331.
54. Richon, V. M.; Zhou, X.; Secrist, J. P.; Cordon-Cardo, C.; Kelly, W. K.; Drobnjak, M.; Marks, P. A. Histone deacetylase inhibitors: assays to assess effectiveness in vitro and in vivo. Methods Enzymol. 2004, 376, 199-205.
55. Beckers, T.; Burkhardt, C.; Wieland, H.; Gimmnich, P.; Ciossek, T.; Maier, T.; Sanders, K. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int. J. Cancer 2007, 121, 1138-1148.
56. Glaser, K. B.; Li, J.; Pease, L. J.; Staver, M. J.; Marcotte, P. A.; Guo, J.; Frey, R. R.; Garland, R. B.; Heyman, H. R.; Wada, C. K.; Vasudevan, A.; Michaelides, M. R.; Davidsen, S. K.; Curtin, M. L. Differential protein acetylation induced by novel histone deacetylase inhibitors. Biochem. Biophys. Res. Commun. 2004, 325, 683-690.
57. Lee, Y. S.; Lim, K. H.; Guo, X.; Kawaguchi, Y.; Gao, Y.; Barrientos, T.; Ordentlich, P.; Wang, X. F.; Counter, C. M.; Yao, T. P. The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res. 2008, 68, 7561-7569.
58. Kwon, H. J.; Owa, T.; Hassig, C. A.; Shimada, J.; Schreiber, S. L. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc. Natl. Acad. Sci. USA 1998, 95, 3356-3361.
59. Taddei, A.; Roche, D.; Bickmore, W. A.; Almouzni, G. The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy? EMBO Rep. 2005, 6, 520-524.
60. Riss, T. L.; Moravec, R. A. Use of multiple assay endpoints to investigate the effects of incubation time, dose of toxin, and plating density in cell-based cytotoxicity assays. Assay Drug Dev. Technol. 2004, 2, 51-62.
61. Belien, A.; De Schepper, S.; Floren, W.; Janssens, B.; Marien, A.; King, P.; Van Dun, J.; Andries, L.; Voeten, J.; Bijnens, L.; Janicot, M.; Arts, J. Real-time gene expression analysis in human xenografts for evaluation of histone deacetylase inhibitors. Mol. Cancer Ther. 2006, 5, 2317-2323.
62. Curtin, M.; Glaser, K. Histone deacetylase inhibitors: the Abbott experience. Curr. Med. Chem. 2003, 10, 2373-2392.
63. Glaser, K. B.; Li, J.; Staver, M. J.; Wei, R. Q.; Albert, D. H.; Davidsen, S. K. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem. Biophys. Res. Commun. 2003, 310, 529-536.
64. Ashburner, B. P.; Westerheide, S. D.; Baldwin, A. S., Jr. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol. Cell Biol. 2001, 21, 7065-7077.
65. Scott, G. K.; Marden, C.; Xu, F.; Kirk, L.; Benz, C. C. Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen. Mol. Cancer Ther. 2002, 1, 385-392.
66. Grozinger, C. M.; Schreiber, S. L. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem. Biol. 2002, 9, 3-16.